NetworkNewsBreaks

TuesdayNov 15, 2016 3:26 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on November 15, 2016

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: LOGX 54.64% – News: Inks deal with established financial services firm NPHC 40.00% – News: Initiated infomercial test campaign for OTC drug for pain in animals UVND 32.81% – News: Posts over 50% revenue increase in Q3 NMUS 30.95% – News: Will present NB1111 data at 2016 AAPS national meeting CLRB 30.11% – News: Selects INC Research (NASDAQ: INCR) to oversee phase 2 clinical trial of CLR 131 BLIN 32.02% – News: iAPPS platform…

Continue Reading

TuesdayNov 15, 2016 1:09 pm

Marathon Patent Group, Inc. (MARA) Subsidiary Inks Licensing Deal with the University of Cincinnati; Shares Lower

3D Nanocolor Corporation, a subsidiary of Marathon Patent Group (NASDAQ: MARA), has entered into an exclusive license agreement with the University of Cincinnati covering the company’s patent-pending applications based on 3D Nanocolor's electrokinetic (EK) technology. 3D Nanocolor will showcase a prototype of the technology early next year. "The recent addition of two highly capable and accomplished technologists with specific experience in our field of technology, combined with our prototype of our technology being showcased to executives of a leading European automobile manufacturer in early 2017, gives us cause for optimism. We are working diligently and looking forward to the opportunity…

Continue Reading

TuesdayNov 15, 2016 1:07 pm

Immunomedics, Inc. (IMMU) Receives 4 New Patents for Expanded Antibody-Drug Conjugate Program

Immunomedics (NASDAQ: IMMU) this morning announced it has received patent protection for the use of IMMU-132, the company’s lead antibody-drug conjugate (ADC) for the treatment of patients with Trop-2-positive cancers. Based on “encouraging objective response rates and durable responses” from an ongoing phase 2 clinical study, Immunomedics said it plans to expand its ADC program to include liquid tumors. As a result, the company created and received a patent for IMMU-140, as well as another ADC targeting B-cell hematologic malignancies. All three new ADC patents will expire in July 2033. Additionally, Immunomedics’ IBC Pharmaceuticals, Inc. subsidiary has received a patent…

Continue Reading

TuesdayNov 15, 2016 1:05 pm

Viking Therapeutics, Inc. (VKTX) Presents Additional Results of VK2809 for Treatment of High Cholesterol; Shares Higher

Viking Therapeutics (NASDAQ: VKTX) is trading higher after the clinical-stage biopharmaceutical company announced additional data from its previously completed phase 1b clinical trial designed to evaluate the safety and tolerability of VK2809 in subjects with mild hypercholesterolemia, or high cholesterol. As presented in a poster presentation earlier this week at the American Heart Association (AHA) Scientific Sessions 2016 in New Orleans, the new results show VK2809's effect on additional proteins associated with cardiovascular disease. "These data support the promise of thyroid beta-targeted approaches for the treatment of cardiovascular and other metabolic diseases.  We previously reported results showing VK2809's ability to…

Continue Reading

TuesdayNov 15, 2016 11:33 am

Fusion Telecommunications (FSNN) Trades Higher on Apptix Acquisition, Q3 Performance, New Credit Facility

Shares of Fusion Telecommunications (NASDAQ: FSNN) are 10% higher after the company announced its acquisition of Virginia-based cloud services provider Apptix, Inc. for $28 million, as well as reported third-quarter revenue of $29.5 million and a $70 million credit facility. Fusion attributes the 20% YoY increase in consolidated revenue to revenue growth of 27% from its Business Services segment. To view the full press release, visit: http://nnw.fm/0zz9C About Fusion Fusion, a leading provider of integrated cloud solutions to small, medium and large businesses, is the industry's single source for the cloud. Fusion's advanced, proprietary cloud service platform enables the integration…

Continue Reading

TuesdayNov 15, 2016 11:31 am

Moxian, Inc. (MOXC) Raises $10M in Public Offering, Uplists to NASDAQ

Moxian, Inc. (NASDAQ: MOXC) this morning made its debut on the NASDAQ Capital Market after a successful uplist from the OTCQB. The provider of an innovative offline-to-online (O2O) integrated social media platform also announced the completion of its public offering, for which it expects gross proceeds of about $10 million. To view the full press release, visit: http://nnw.fm/Rq2EN About Moxian, Inc. Moxian (MOXC) engages in the business of providing social marketing and promotion platforms to merchants who desire to promote their businesses through online social media. The company’s products and services aim to enhance the interaction between users and merchant…

Continue Reading

MondayNov 14, 2016 2:41 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on November 14, 2016

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: PFTI 42.59% - News: Conversion cuts long-term debt 47% to $7M MCIG 31.53% - News: Turns to profit, Q2 revenues increase 126% from Q1 ENTK 30.77% - News: Inks deal with State Bicycle Co. to build virtual store in Hypatia WARM 20.40% - News: Says Mobile Generation technology is near completion GRWG 28.26% - News: Posts record Q3, nine-month financial results OBCI 18.81% - News: Record Q3 performance; earnings of $1.5M on sales of…

Continue Reading

MondayNov 14, 2016 12:06 pm

Celldex Therapeutics (CLDX): CDX-1140 Data Shows Potential; Shares Climb

Shares of Celldex Therapeutics (NASDAQ: CLDX) are higher Monday morning after the company said it presented data on new product candidate CDX-1140, a fully human antibody targeted to CD40 that has demonstrated potent agonist activity. The data were presented over the weekend at the Society for Immunotherapy of Cancer Annual Meeting (SITC). Key findings include: CDX-1140 binds CD40 with high affinity and specificity and does not block CD40 ligand binding CDX-1140 has an unmodified IgG2 backbone and demonstrates potent agonist activity independent of Fc receptor interactions CDX-1140 demonstrates direct anti-tumor activity in immune-deficient mice challenged with human lymphomas Pharmacological activity…

Continue Reading

MondayNov 14, 2016 12:03 pm

FDA Response Triggers Dynavax Technologies (DVAX) Sell-off

Dynavax Technologies (NASDAQ: DVAX) is down more than 60% mid-morning after the company said it received a Complete Response Letter (CRL) from the FDA regarding its Biologics License Application (BLA) for its HEPLISAV-B™ vaccine against hepatitis B infection. The CRL signals the FDA’s completed a review of an application and stands as a request for additional information for review and approval. Dynavax said it expects a Class 2 designation for a resubmission of the BLA, which would result in a target review period of six months. To view the full press release, visit: http://nnw.fm/9mS6x About Dynavax Dynavax, a clinical-stage biopharmaceutical…

Continue Reading

MondayNov 14, 2016 12:00 pm

National Waste Management Holdings, Inc. (NWMH) is Active Participant in Florida’s Statewide Recycling Initiative

The State of Florida is working toward a statewide recycling goal of 75% by the year 2020. The journey to such a high bar is a lengthy one. While the state’s recycling rate increased by 4% between 2012 and 2013, the amount of solid waste has also increased, from just under 28 million tons to over 30 million. Florida’s Department of Environmental Protection believes that more commercial recycling would help reach its goal of 75%, and National Waste Management Holdings, Inc. (OTC: NWMH) is addressing the challenge head on. Reporting third-quarter revenue growth of 269%, National Waste employs a strategic…

Continue Reading